Market capitalization | $1.47b |
Enterprise Value | $746.29m |
P/E (TTM) P/E ratio | 10.00 |
EV/FCF (TTM) EV/FCF | 4.58 |
EV/Sales (TTM) EV/Sales | 1.79 |
P/S ratio (TTM) P/S ratio | 3.53 |
P/B ratio (TTM) P/B ratio | 1.96 |
Revenue growth (TTM) Revenue growth | -16.16% |
Revenue (TTM) Revenue | $416.63m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
6 Analysts have issued a Inmode forecast:
6 Analysts have issued a Inmode forecast:
Dec '23 |
+/-
%
|
||
Net Profit | 198 198 |
23%
23%
|
|
Depreciation and Amortization | 0.62 0.62 |
9%
9%
|
|
Stock Compensation | 24 24 |
3%
3%
|
|
Operating Cash Flow | 177 177 |
3%
3%
|
|
Investments | 0.71 0.71 |
55%
55%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | 176 176 |
2%
2%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. It also designs, develops, manufactures and markets non-invasive medical aesthetic products that target a array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture and superficial benign vascular and pigmented lesions. The company was founded by Moshe Mizrahy and Michael Kreindel on January 2, 2008 and is headquartered in Yokneam, Israel.
Head office | Israel |
CEO | Moshe Mizrahy |
Employees | 581 |
Founded | 2008 |
Website | www.inmodemd.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.